Using a technology called optical stretching, investigators found that they could distinguish oral cancer cells from normal cells based on how soft or deformable they were.
The five-year award will go toward developing a tool that will be based on digitized hematoxylin and eosin (H&E)-stained pathology images alone.
The company is developing a companion diagnostic to identify head and neck cancer patients most likely to benefit from Erbitux.
The company's PD-L1 IHC 28-8 pharmDx diagnostic can now be used in cases of urothelial carcinoma and squamous cell carcinoma of the head and neck.
New data now suggests that evaluating PD-L2 levels might better predict response to PD-1 targeting immune-oncology drugs than current tests that only measure PD-L1.